23 and me glp-1 23andMe Reports Genetic Predictors of Response to Drugs for Obesity If you aren't losing weight
Description
Enhances Natural GLP-1 Activity
How It Works
A new study finds cognitive decline in patients taking GLP-1 medications for longer than 10 years, yet researchers say it may be the result of those patients living longer than their peers.
So Whats Wrong With Pharmaceuticals
The new formulation of the obesity drug places Novo a step ahead of its competitor, Eli Lilly, whose rival drug orforglipron is still being assessed by regulators
